GM-CSF Binding Proteins Neutralize Inflammatory Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for GM-CSF inhibitors to address the inflammatory and autoimmune diseases associated with elevated levels of GM-CSF, as current treatments can exacerbate conditions or have limited efficacy.
Innovation Solution
Development of antigen-binding proteins that specifically bind to GM-CSF, inhibiting its signaling and reducing monocyte migration and accumulation in tumors, which can be used to treat conditions like multiple sclerosis, rheumatoid arthritis, and other inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for GM-CSF-related diseases, then treatment is provided, but conditions are exacerbated or efficacy is limited
Solution Approach 1:
The patent develops antigen-binding proteins that specifically target and neutralize GM-CSF, converting the harmful effect of elevated GM-CSF levels (which causes inflammation and autoimmune diseases) into a beneficial therapeutic outcome. By binding to GM-CSF and preventing its interaction with the GM-CSF receptor, these proteins eliminate the harmful inflammatory and autoimmune responses while preserving normal physiological functions.
Solution Approach 2:
The antigen-binding proteins serve as intermediary molecules that intervene between GM-CSF and its receptor. These proteins bind to GM-CSF with high affinity, acting as a mediator that prevents direct GM-CSF-receptor interaction, thereby blocking the harmful signaling cascade without directly modifying GM-CSF or the receptor structures.
2Object-generated harmful factors
If GM-CSF activity is inhibited to reduce inflammation, then autoimmune responses are ameliorated, but normal hematopoietic functions may be affected
Solution Approach 1:
The antigen-binding proteins exhibit local quality by selectively targeting pathogenic GM-CSF activity in inflammatory and autoimmune contexts while sparing normal physiological functions. The proteins bind with high specificity to GM-CSF, creating a localized therapeutic effect at the site of inflammation without broadly suppressing all GM-CSF-mediated processes, including normal hematopoiesis.
Solution Approach 2:
The invention changes the parameter of GM-CSF availability by reducing free GM-CSF concentration through specific binding, rather than altering the fundamental properties of GM-CSF or its receptor. This parameter change (decreasing bioavailable GM-CSF) selectively reduces pathological inflammation while maintaining sufficient GM-CSF levels for normal hematopoietic functions.
3Object-generated harmful factors
If antigen-binding proteins are developed to specifically bind GM-CSF, then GM-CSF signaling is inhibited and monocyte migration is reduced, but protein complexity increases
Solution Approach 1:
The antigen-binding proteins utilize the natural binding interface between GM-CSF and its receptor as a template, copying the key interaction features to design proteins that specifically neutralize GM-CSF. By mimicking the receptor's binding site characteristics, these proteins achieve high-specificity GM-CSF inhibition without requiring complex multi-component systems.
Data Source
AI summary
Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.